Acute cerebral circulatory disorders and coronavirus disease

The new COVID-19 coronavirus infection caused by SARS-CoV-2 is a global health threat. Neurological disorders detected in patients with coronavirus infection have a wide range of clinical signs: headache, dizziness, altered level of consciousness, acute ischemic stroke, intracerebral hemorrhage, cerebral venous sinus thrombosis. Evidence suggests that patients with more severe systemic symptoms were more likely to experience neurological symptoms. The main risk factors for the development of ischemic stroke in patients with coronavirus infection are considered. It was shown that COVID-19 more often occurred in people with vascular risk factors, among which the mortality rate was higher. Various possible and not mutually exclusive mechanisms which may play a role in the development of ischemic stroke in patients with COVID-19 are described in detail, including hyper-inflammatory state («cytokine storm»), «COVID-19-associated coagulopathy», and disseminated intravascular coagulation syndrome. Stroke risk factors associated with the critical condition in these patients are presented. Stroke, the leading cause of death and disability worldwide, requires immediate treatment and decision-making as well as 24/7 availability for specialized vascular centers. The results of observation of patients with acute cerebral circulation disorder in specialized vascular centers 2 months before and 15 days after quarantine due to COVID-19 are presented. The tactics of managing patients with ischemic stroke under conditions of coronavirus infection is considered.

1. Helms J., Kremer S., Merdji H., Clere-Jehl R., Schenck M., Kummerlen C., Collange O. et al. Neurologic Features in Severe SARS-CoV-2 Infection. N Engl J Med. 2020;382(23):2268–2270. doi: 10.1056/NEJMc2008597.

2. Chen T., Wu D., Chen H., Yan W., Yang D., Chen G. et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study [published correction appears in BMJ. 2020 Mar 31;368:m1295]. BMJ. 2020;368:m1091. doi: 10.1136/bmj.m1091.

3. Divani А.А., Andalib S., Di Napoli V., Lattanzi S., Hussain M.S., Biller J. et al. Coronavirus Disease 2019 and Stroke: Clinical Manifestations and Pathophysiological Insights. J Stroke Cerebrovasc Dis. 2020;29(8):104941.doi: 10.1016/j.jstrokecerebrovasdis.2020.104941.

4. Zhao J., Rudd A., Liu R. Challenges and Potential Solutions of Stroke Care During the Coronavirus Disease 2019 (COVID-19) Outbreak. Stroke. 2020;51(5):1356–1357. doi: 10.1161/STROKEAHA.120.029701.

5. Sharifi-Razavi A., Karimi N., Rouhani N. COVID-19 and intracerebral haemorrhage: causative or coincidental?. New Microbes New Infect. 2020;35:100669. doi: 10.1016/j.nmni.2020.100669.

6. Qin C., Zhou L., Hu Z., Yang S., Zhang S., Chen M. et al. Clinical Characteristics and Outcomes of COVID-19 Patients With a History of Stroke in Wuhan, China. Stroke. 2020;51(7):2219–2223. doi: 10.1161/STROKEAHA.120.030365.

7. Yaghi S., Ishida K., Torres J., Mac Grory B., Raz E., Humbert K. et al. SARS2- CoV-2 and Stroke in a New York Healthcare System. Stroke. 2020;51(7):2002–2011. doi: 10.1161/STROKEAHA.120.030335.

8. Mao L., Jin H., Wang M., Chen S., He Q., Chang J. et al. Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. JAMA Neurol. 2020;77(6):1–9. doi: 10.1001/jamaneurol.2020.1127.

9. Li Y., Wang M., Zhou Y., Chang J., Xian Y., Mao L. et al. Acute cerebrovascular disease following COVID-19: a single center, retrospective, observational study. SSRN Electronic Journal. 2020. doi: 10.2139/ssrn.3550025.

10. Weston S., Frieman M.B. COVID-19: Knowns, Unknowns, and Questions. mSphere. 2020;5(2):e00203–20. doi: 10.1128/mSphere.00203-20.

11. Yang J., Zheng Y., Gou X., Pu K., Chen Z., Guo Q. et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis. 2020;94:91–95. doi: 10.1016/j.ijid.2020.03.017.

12. Emami A., Javanmardi F., Pirbonyeh N., Akbari A. Prevalence of Underlying Diseases in Hospitalized Patients with COVID-19: a Systematic Review and Meta-Analysis. Arch Acad Emerg Med. 2020;8(1):e35. Available at: https://pubmed.ncbi.nlm.nih.gov/32232218.

13. Klok F.A., Kruip M.J.H.A., van der Meer N.J.M., Arbous M.S., Gommers D.A.M.P.J., Kant K.M. et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145–147. doi: 10.1016/j.thromres.2020.04.013.

14. Zhou F., Yu T., Du R., Fan G., Liu Y., Liu Z. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3.

15. Onder G., Rezza G., Brusaferro S. Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. JAMA. 2020. doi: 10.1001/jama.2020.4683.

16. Chen G., Wu D., Guo W., Cao Y., Huang D., Wang H. et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020;130(5):2620–2629. doi: 10.1172/JCI137244.

17. ti P., Ronconi G., Caraffa A., Gallenga C.E., Ross R., Frydas I. et al. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. J Biol Regul Homeost Agents. 2020;34(2):1. doi: 10.23812/CONTI-E.

18. Hamming I., Timens W., Bulthuis M.L., Lely A.T., Navis G., van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004;203(2):631-637. doi: 10.1002/path.1570.

19. Arabi Y.M., Balkhy H.H., Hayden F.G., Bouchama A., Luke T., Baillie J.K. et al. Middle East Respiratory Syndrome. N Engl J Med. 2017;376(6):584–594. doi: 0.1056/NEJMsr1408795.

20. Vaninov N. In the eye of the COVID-19 cytokine storm. Nat Rev Immunol. 2020;20(5):277. doi: 10.1038/s41577-020-0305-6.

21. Tang N., Li D., Wang X., Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(4):844–847. doi: 10.1111/jth.14768.

22. Wu C., Chen X., Cai Y., Xia J., Zhou X., Xu S. et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. 2020. doi: 10.1001/jamainternmed.2020.0994.

23. Lippi G., Plebani M. Procalcitonin in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis. Clin Chim Acta. 2020;505:190–191. doi: 10.1016/j.cca.2020.03.004.

24. Zhang Y., Xiao M., Zhang S., Xia P., Cao W., Jiang W. et al. Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19. N Engl J Med. 2020;382(17):e38. doi: 10.1056/NEJMc2007575.

25. Varga Z., Flammer A.J., Steiger P., Haberecker M., Andermatt R., Zinkernagel A.S. et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395(10234):1417–1418. doi: 10.1016/S0140-6736(20)30937-5.

26. Bonetti P.O., Lerman L.O., Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol. 2003;23(2):168–175. doi: 10.1161/01.atv.0000051384.43104.fc.

27. Flammer A.J., Anderson T., Celermajer D.S., Creager M.A., Deanfield J., Ganz P. et al. The assessment of endothelial function: from research into clinical practice. Circulation. 2012;126(6):753–767. doi: 10.1161/CIRCULATIONAHA.112.093245.

28. Ding Y., Wang H., Shen H., Li Z., Geng J., Han H. et al. The clinical pathology of severe acute respiratory syndrome (SARS): a report from China. J Pathol. 2003;200(3):282–289. doi: 10.1002/path.1440.

29. Wang C., Pan R., Wan X., Tan Y., Xu L., Ho C.S., Ho R.C. Immediate Psychological Responses and Associated Factors during the Initial Stage of the 2019 Coronavirus Disease (COVID-19) Epidemic among the General Population in China. Int J Environ Res Public Health. 2020;17(5):1729. doi: 10.3390/ijerph17051729.

30. Khosravani H., Rajendram P., Notario L., Chapman M.G., Menon B.K. Protected Code Stroke: Hyperacute Stroke Management During the Coronavirus Disease 2019 (COVID-19) Pandemic. Stroke. 2020;51(6):1891–1895. doi: 10.1161/STROKEAHA.120.029838.

31. Montaner J., Barragán-Prieto A., Pérez-Sánchez S., Escudero-Martínez I., Moniche F., Sánchez-Miura J.A. et al. Break in the Stroke Chain of Survival Due to COVID-19. Stroke. 2020. doi: 10.1161/STROKEAHA.120.030106.

32. Klijn C.J., Paciaroni M., Berge E., Korompoki E., Kõrv J., Lal A. et al. Antithrombotic treatment for secondary prevention of stroke and other thromboembolic events in patients with stroke or transient ischemic attack and non-valvular atrial fibrillation: A European Stroke Organisation guideline. Eur Stroke J. 2019;4(3):198–223. doi: 10.1177/2396987319841187.

33. Palnum K.H., Mehnert F., Andersen G., Ingeman A., Krog B.R., Bartels P.D., Johnsen S.P. Use of secondary medical prophylaxis and clinical outcome among patients with ischemic stroke: a nationwide follow-up study. Stroke. 2012;43(3):802–807. doi: 10.1161/STROKEAHA.111.635342.

34. Asberg S., Henriksson K.M., Farahmand B., Asplund K., Norrving B., Appelros P. et al. Ischemic stroke and secondary prevention in clinical practice: a cohort study of 14,529 patients in the Swedish Stroke Register. Stroke. 2010;41(7):1338–1342. doi: 10.1161/STROKEAHA.110.580209.

35. Bernhardt J., Dewey H., Thrift A., Collier J., Donnan G. A very early rehabilitation trial for stroke (AVERT): phase II safety and feasibility. Stroke. 2008;39(2):390–396. doi: 10.1161/STROKEAHA.107.492363.

36. Veerbeek J.M., van Wegen E., van Peppen R., van der Wees P.J., Hendriks E., Rietberg M., Kwakkel G. What is the evidence for physical therapy poststroke? A systematic review and meta-analysis. PLoS One. 2014;9(2):e87987. doi: 10.1371/journal.pone.0087987.

37. Tanashyan M.M., Domashenko M.A., Maksimova M.Yu. Current approaches to neuroprotection as a part of complex acute stroke treatment and early rehabilitation. Nervnye bolezni = Nervous Diseases. 2017;(3):36–41. (In Russ.) Available at: https://www.neurology.ru/sites/default/files/assets/documents/2017/11/nb-3-2017-36.pdf?download=1.

38. Prokopenko S.V., Shanina E.G., Petrova M.M., Mozheyko E.Yu. Neurorestoration: modern views on the problem. Farmateka. 2014;(13):20–24. https://pharmateca.ru/ru/archive/article/30171.

39. Romanova G.A., Shakova F.M., Barskov I.V., Stel’mashuk E.V., Petrov T.V., Sokolov M.A. et al. Effect of celleks on functional and morphological changes in experimental focal ischemia of prefrontal areas of the rat brain cortex. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2010;110(9):52–56. (In Russ.) Available at: https://www.mediasphera.ru/issues/zhurnal-nevrologii-ipsikhiatrii-im-s-s-korsakova/2010/9/031997-72982010910.

40. Khasanova D.P., Danilova T.V., Demin T.V., Knni K.S., Gaifutdinova L.V. The effect of cellex on the recovery of motor and speech functions during early neurorehabilitation of patients with ischemic stroke. Meditsinskiy sovet = Medical Council. 2018;(9):14–19. (In Russ.) doi: 10.21518/2079-701X-2018-9-14-19.

41. Pizova N.V., Sokolov M.A., Izmajlov I.A. Cellex in the treatment of patients with acute disturbance of cerebral blood circulation: results of a multicenter comparative open clinical trial. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2014;114(5):22–26. (In Russ.) Available at: https://www.mediasphera.ru/issues/zhurnal-nevrologii-i-psikhiatrii-im-s-s-korsakova/2014/5/031997-7298201454.

42. Belskaya G.N., Pizova N.V., Sokolov M.A., Izmalov I.A. Neuroprotection influence on course of cerebral stroke. Meditsinskiy sovet = Medical Council. 2016;(11):26–31. (In Russ.) doi: 10.21518/2079-701X-2016-11-26-31.

43. Belskaya G.N., Chuprina S.E., Vorobyev A.A., Gorozha E.N., Butorakina T.L., Sokolov M.A., Izmaylov I.A. Cognitive disorders in stroke patients: the possibilities of pharmacological correction. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2016;5(116):33–37. (In Russ.) doi: 10.17116/jnevro20161165133-37.

44. Kotov S.V., Belova Yu.A., Shcherbakova M.M., Chervinskaya A.D., Isakova E.V., Volchenkova E.V. Restoring of the speech functions in patients with aphasia in the early rehabilitation period of ischemic stroke. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(2):38–41. (In Russ.) doi: 10.17116/jnevro20171172138-41.

45. Kovalenko A.V., Safronova M.N. The effect of cellex on cognitive and speech impairments in the acute stage of stroke. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2015;115(1):40–44. (In Russ.) doi: 10.17116/jnevro20151151140-44.

46. Belskaya G.N., Krilova L.G., Sokolov M.A., Izmailov I.A. Possibilities of the treatment of speech impairment in the acute stage of ischemic stroke using neuroprotective therapy. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2015;115(9):60–63. (In Russ.) doi: 10.17116/jnevro20151159260-63.

47. Kovalchuk V.V., Gusev A.O., Minnullin T.I., Nesterin K.V. Post-Stroke Rehabilitation. Efficacy Criteria and Success Factors: a Role of Physical, Neuropsychological and Drug Therapy. Ehffektivnaya farmakoterapiya. Nevrologiya i psikhiatriya. Spetsvypusk «Mysli, znaniya i opyt vedushchikh uchenykh-nevrologov Sankt-Peterburga». = Effective Pharmacotherapy. Neurology and Psychiatry. Special Issue “Thoughts, Knowledge and Experience of Leading Researchers-Neurologists of Saint Petersburg”. 2017;(19):62–73. (In Russ.) Available at: https://umedp.ru/articles/reabilitatsiya_patsientov_posle_insulta_kriterii_effektivnosti_i_faktory_uspekha_rol_fizicheskoy_ney.html.